Tom Keith-Roach — SPARQNOW

At-a-Glance

President of AstraZeneca UK since 2020, growing the business from 14th to 2nd in the UK market by sales (Q4 2023).
Served as Global SVP of AstraZeneca’s $5.5bn Respiratory & Immunology Division (2015-2020), returning it to strong growth (up to 16% in FY 2019 and 20% in Q1 2020).
Led late-stage development and commercial strategy for products including Fasenra, Tezpire, Saphnelo, Airsupra, Breztri, Bevespi, and Symbicort Mild Asthma.
Engaged externally with the UK Government and stakeholders on COVID response, a new £80bn VPAG deal, and AZ’s £650m investment in Speke and Cambridge.
Served as Global VP, Brilinta Task Force (2012-2015), building new R&D and commercial strategies for the $2bn global brand Brilinta (ticagrelor).

Biography

Tom Keith-Roach is a dynamic lifesciences executive currently serving as the President of AstraZeneca UK, a position he has held since 2020. Under his leadership, AstraZeneca UK overhauled its strategy and grew significantly, moving from 14th to 2nd in the UK market by sales in Q4 2023.